Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube

ISPOR 11th Annual International Meeting
May 20-24, 2006  Marriott Philadelphia, Philadelphia, PA
 

CONTRIBUTED POSTER PRESENTATIONS SESSION II


 

Infection

   
PIN1 HEPATOTOXICITY ASSOCIATED WITH RIFAMPIN AND PYRAZINAMIDE THERAPY OF LATENT TUBERCULOSIS INFECTION: A META-ANALYSIS
Ghosh S
University of Louisiana at Monroe, Monroe, LA, USA
   
PIN2 COST COMPARISON OF A ONCE-DAILY PARENTERAL ANTIBIOTIC IN HOSPITAL SETTINGS: INFORMATION FROM THE SIDESTEP STUDY
Turpin RS1, Tice A2, Wu JH1, Taylor S1, Polis A1, Abramson M1
1Merck & Co., Inc, West Point, PA, USA, 2University of Hawaii, Honolulu, HI, USA
   
PIN3 THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C: THE IMPACT OF USING RECOMBINANT HUMAN ERYTHROPOETIN
Cross JT, Devine EB, Kowdley KV, Sullivan SD
University of Washington, Seattle, WA, USA
   
PIN4 ECONOMIC ANALYSIS OF LATENT TUBERCULOSIS INFECTION (LTBI) SCREENING IN MILITARY RECRUITS: QUANTIFERON®-TB GOLD IN-TUBE (QFT-GIT) VERSUS TUBERCULIN SKIN TESTING (TST)
Nevin R
Army Medical Surveillance Activity, Washington, DC, USA
   
PIN5 Withdrawn
   
PIN6 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXICOLATE FOR THE PRIMARY TREATMENT OF INVASIVE ASPERGILLOSIS
Aiello EC1, Devoto FM2, Dignani C3, De Vedia L4, Lorenzo H5
1Pfizer Argentina, Buenos Aires, Argentina, 2University of Buenos Aires, Buenos Aires, Argentina, 3Fundaleu, Buenos Aires, Argentina, 4Hospital Muñiz, Buenos Aires, Argentina, 5Pfizer Argentina, Buenos Aires, Argentina
   
PIN7 WITHDRAWN
   
PIN8 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA IN ARGENTINA
Aiello EC1, Barcelona LI2, De Vedia L3, Stamboulian D2
1Pfizer Argentina, Buenos Aires, Argentina, 2FUNCEI, Buenos Aires, Argentina, 3Hospital Muñiz, Buenos Aires, Argentina
   
PIN9 ECONOMIC EVALUATION FOR THE ANTIMICROBIAL EMPIRIC TREATMENT OF HOSPITALIZED PATIENTS WITH VENTILATOR – ASSOCIATED PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS IN MEXICO
Contreras-Hernandez I, Mould J, Suárez-Nuñez F, Garduño-Espinosa J
Social Security Mexican Institute, Mexico City, Mexico
   
PIN10 COST EFFECTIVENESS OF TIPRANAVIR IN TREATMENT-EXPERIENCED HIV PATIENTS IN THE USA
Simpson KN1, Chumney ECG1, Hicks CB2, Finnern H3
1Medical University of South Carolina, Charleston, SC, USA, 2Duke University Medical Center, Durham, NC, USA, 3Boehringer Ingelheim GmbH, Ingelheim, Germany
   
PIN11 THE IMPACT OF MECHANICAL VENTILATION ON OUTCOMES AND COSTS IN NOSOCOMIAL PNEUMONIA
Neslusan C1, Nuyts G2, Stellhorn R1
1Johnson and Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 2Johnson and Johnson, Raritan, NJ, USA
   
PIN12 LIFETIME MEDICAL COST OF CHRONIC HEPATITIS B
Miriti MK, Billah K, Weinbaum C, Meltzer M
Centers for Disease Control and Prevention, Atlanta, GA, USA
   
PIN13 COST OF THERAPY OF UPPER RESPIRATORY TRACT INFECTIONS IN A DEPRESSED ECONOMY
Suleiman IA, Tayo F, Mendie U
Faculty of Pharmacy, University of Lagos, Lagos, Nigeria
   
PIN14 DIRECT MEDICAL COSTS OF PATIENTS WITH HIV/AIDS IN MEXICO
Contreras-Hernandez I1, Morales-Cisneros G1, Mould J1, Salinas-Escudero G1, Rely K2, Garduño-Espinosa J1
1Social Security Mexican Institute, Mexico City, Mexico, 2Pharmacoeconomic Consultor, Mexico City, Mexico
   
PIN15 THE EXPECTED ECONOMIC BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI)
Mallick R1, Kuznik A1, Weber D2
1Wyeth Research, Collegeville, PA, USA, 2University of North Carolina, Chapel Hill, NC, USA
   
PIN16 CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN ACUTE HOSPITALS: A PREVALENT COST ISSUE
O'Brien JA1, Pitoniak-Morse C1, Lahue BJ2, Davidson D2, Wilson D2, Caro JJ1
1Caro Research Institute, Concord, MA, USA, 2Genzyme Corporation, Cambridge, MA, USA
   
PIN17 A COST-UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A VERSUS PEGINTERFERON ALFA-2B AS THE INITIAL TREATMENT OF HEPATITIS C FROM THE PERSPECTIVE OF THE VETERANS AFFAIRS HEALTH CARE SYSYTEM
Yeh WS1, Armstrong EP2, Skrepnek GH2, Malone DC2
1University of North Carolina, Chapel Hill, NC, USA, 2University of Arizona, Tucson, AZ, USA
   
PIN18 HOSPITAL LENGTH-OF-STAY AND COSTS ASSOCIATED WITH USE AND EARLIER INITIATION OF DROTRECOGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH THE HIGHEST PROPENSITY OF HAVING SEVERE SEPSIS
Ernst FR1, Viswanathan S2, Vedarajan G3, Reynolds J3, Kohli B3
1Eli Lilly and Company, Indianapolis, IN, USA, 2ZS Associates, Boston, MA, USA, 3ZS Associates, Evanston, IL, USA
   
PIN19 WITHDRAWN
   
PIN20 COMPARISON OF HEALTH OUTCOMES AMONG SEVERE COMMUNITY-ACQUIRED PNEUMONIA PATIENTS TREATED EMPIRICALLY WITH A BETA-LACTAM PLUS A MACROLIDE VERSUS A BETA-LACTAM PLUS A FLUOROQUINOLONE
Frei CR1, Restrepo MI2, Mortensen EM3, Burgess DS4
1University of Texas at Austin and University of Texas Health Sci. Ctr. at San Antonio, San Antonio, TX, USA, 2University of Texas Health Sci. Ctr. at San Antonio, Vet. Evidence-Based Res. Dis. and Imp. Ctr, and South TX Health Care System, San Antonio, TX, USA, 3Univ. TX Health Sci. Ctr. at San Antonio, Vet. Evidence-Based Res. Dis. and Imp. Ctr, and South TX Health Care System, San Antonio, TX, USA, 4Univ. TX at Austin and Univ. TX Health Sci. Ctr. at San Antonio, San Antonio, TX, USA
   
PIN21 USE OF EVIDENCE BASED MODELS TO DEMONSTRATE THE LONG-TERM CLINICAL BENEFITS OF HPV VACCINATION.
Bernard L1, Lindsay L2, Rogoza R1, Kohli MA1, Franco EL3
1Innovus Research Inc, Burlington, ON, Canada, 2GSK Biologicals, Rixensart, Belgium, 3McGill University, Montreal, QC, Canada
   
PIN22 USE OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING WITH MONTE CARLO SIMULATION TO REDUCE ANTIBIOTIC EXPENDITURES WITHOUT COMPROMISING PREDICTED EFFICACY
Frei CR1, Lewis JS2, Burgess DS1
1University of Texas at Austin and University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, 2University of Texas at Austin and University of Texas Health Science Center at San Antonio and University Health System, San Antonio, TX, USA
   
PIN23 A REVIEW OF HERD EFFECTS IN THE ECONOMIC EVALUATION OF CHILDHOOD VACCINATIONS
Vicente C1, McKinnon K1, Ciuryla V2, Han D1
1Wyeth Pharmaceuticals, Markham, ON, Canada, 2Wyeth Research, Collegeville, PA, USA
   


Contributed Posters Session I

 


11th Annual Meeting Main Page
 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.